BioByte 075: Next generation antibodies, CRISPR beyond the liver, 85 Million cells at your fingertips
BioByte 074: Why Mars is tough for life, an autoantibody signature for MS, selective compartmentalization for proteins, AI-designed CRISPR, RNAi-based drug design
BioByte 073: citizen science for DNA sequence alignment, cellular niches, updates in AI antibody design, polarizing biotech investment trends
BioByte 072: DNA printing, edible neuromodulatory electronics, AI agents empower biomedical discovery, scRNAseq supports successful drug targets, $100M seed round for gene editing delivery newco
BioByte 071: Unanswered questions, paused base-editing therapy, challenges with ASOs, GPT-4 for cell type annotation, the scientific journey behind Ozempic
BioByte 070: NeuroAI, proteome-scale screening of protein degraders, open source biomedical LLMs, engineering better mRNA therapeutics
BioByte 069: AI learns the meaning of life, the dysfunctome, a $400M launch for inflammatory drugs, Nvidia's 'woodstock' and engineering crops to save the planet
BioByte 068: Cell therapy for solid tumors, using a monoclonal for allergy, improving AlphaFold2 performance, using ML to understand small RNA secretion, Insilico's development of a TNIK inhibitor
BioByte 067: DNA foundation models, neural multi-task learning for drug design, non-invasive methods for brain amyloid clearance, clinical trial architectures for precision medicine
BioByte 066: CAR-T for MS, will AI replace animal testing, diagnosis of ultra-rare monogenic disorders, BigRNA: a foundation model for RNA biology, Matter Neuro raises $26M to “cure unhappiness"
BioByte 065: RNA-editing therapies pick up steam, experts speak on protein design, decoding the autoantibody reactome, links between menopause and healthy aging, and more
BioByte 064: LLMs for neuro, bias in protein language models, engineered T-cell therapeutics inspired by T-cell cancers, AI for molecular glues
BioByte 063: How to develop a blockbuster, unravelling the biology of autoimmunity, partnering with pharma and a new model for intrinsically disordered proteins.
BioByte 062: First RNA-editing trial in US, an integrated classification of Parkinson's, shortening CAR-T manufacturing, cell surface RNAs control neutrophil recruitment
Scaling Biology 002: Gevorg Grigoryan, Co-Founder and CTO at Generate:Biomedicines
BioByte 061: AI for Alzheimer's prediction, NeurIPS 2023 recap, gene therapy for hearing loss, autonomous chemical discovery, and 3D molecular generation
BioByte 060: astrocyte plasticity, a foundation model for RNA structure, improved confidence in biotech activity in '24, predicting therapeutic perturbations, isomorphic's deals
